CGEN-15022 / Compugen - LARVOL DELTA

Compugen (CGEN) reprts updates to collaborative activities with Bayer in immuno-oncology (Streetinsider.com) - "...a recently completed joint assessment by Compugen and Bayer of potential drug candidates against the CGEN-15022 target program has suggested that its potential to serve as a key immune checkpoint for the treatment of cancer immunotherapy may be limited and does not justify further investment. Therefore, it has been determined that the current collaboration will focus solely on CGEN-15001T and all rights to CGEN-15022 will be returned to Compugen."

Licensing / partnership • Oncology